잠시만 기다려 주세요. 로딩중입니다.

High-risk human papillomavirus testing as a primary screening for cervical cancer: position statement by the Korean Society of Obstetrics and Gynecology and the Korean Society of Gynecologic Oncology

Obstetrics & Gynecology Science 2020년 63권 2호 p.107 ~ 107
공태욱 ( Kong Tae-Wook ) - Ajou University School of Medicine Department of Obstetrics and Gynecology

김미선 ( Kim Mi-Seon ) - CHA University School of Medicine CHA Gangnam Medical Center Department of Obstetrics and Gynecology
김영한 ( Kim Young-Han ) - Yonsei University College of Medicine Department of Obstetrics and Gynecology
김용범 ( Kim Yong-Beom ) - Seoul National University Bundang Hospital Department of Obstetrics and Gynecology
김자연 ( Kim Ja-Yeon ) - CHA University School of Medicine CHA Seoul Fertility Center Department of Obstetrics and Gynecology
김재원 ( Kim Jae-Weon ) - Seoul National University College of Medicine Department of Obstetrics and Gynecology
박미혜 ( Park Mi-Hye ) - Ewha Womans University College of Medicine Department of Obstetrics and Gynecology
박주현 ( Park Joo-Hyun ) - Yonsei University College of Medicine Gangnam Severance Hospital Department of Obstetrics and Gynecology
이정호 ( Rhee Jeong-Ho ) - Keimyung University School of Medicine Department of Obstetrics and Gynecology
임명철 ( Lim Myong-Cheol ) - National Cancer Center Center for Uterine Cancer
홍준석 ( Hong Joon-Seok ) - Seoul National University Bundang Hospital Department of Obstetrics and Gynecology

Abstract


Based on emerging data and current knowledge regarding high-risk human papillomavirus (hrHPV) testing as a primary screening for cervical cancer, the Korean Society of Obstetrics and Gynecology and the Korean Society of Gynecologic Oncology support the following scientific facts: · Compared to cytology, hrHPV screening has higher sensitivity and detects more cases of high-grade cervical intraepithelial neoplasia. · Qualified hrHPV testing can be considered as an alternative primary screening for cervical cancer to the current cytology method. · The starting age of primary hrHPV screening should not be before 25 years because of possible overtreatment in this age, which has a high human papillomavirus (HPV) prevalence but rarely progresses to cancer. The screening interval should be no sooner than every 3 years and no longer than every 5 years. · Before the introduction of hrHPV screening in Korea, research into comparative effectiveness of primary hrHPV screening for cervical cancer should be conducted to determine the appropriate HPV assay, starting age, and screening interval.

키워드

Uterine cervical neoplasms; Cancer screening tests; Human papillomavirus DNA tests
원문 및 링크아웃 정보
 
등재저널 정보